The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Selectively Sensitizing Malignant Cells to Photothermal Therapy Using a CD44-Targeting Heat Shock Protein 72 Depletion Nanosystem
Abstract
Selectively enhance the therapeutic efficacy to malignancy is one of the most important issues for photothermal therapy (PTT). However, most solid tumors, such as triple negative breast cancer (TNBC), do not have identifiable surface markers to distinguish themselves from normal cells, thus it is challenging to selectively identify and eliminate those malignances by PTT. In this report, we hypothesized that, by targeting CD44 (one TNBC-overexpressed surface molecule) and depleting heat shock protein 72 (HSP72, one malignancy-specific-overexpressed thermotolerance-related chaperone) subsequently, the TNBC could be selectively sensitized to PTT and improve the accuracy of treatment. To this end, a rationally designed nanosystem gold nanostar (GNS)/siRNA against HSP72 (siHSP72)/hyaluronic acid (HA) was successfully constructed using a layer-by-layer method. Hydrodynamic diameter and zeta potential analysis demonstrated the formation of GNS/siHSP72/HA having a particle size of 73.2 ± 3.8 nm and a negative surface charge of -18.3 ± 1.6 mV. The CD44-targeting ability of GNS/siHSP72/HA was confirmed by the flow cytometer, confocal microscopic imaging, and competitive binding analysis. The HSP72 silencing efficacy of GNS/siHSP72/HA was ∼95% in complete culture medium. By targeting CD44 and depleting HSP72 sequentially, GNS/siHSP72/HA could selectively sensitize TNBC cells to hyperthermia and enhance the therapeutic efficacy to TNBC with minimal side effect both in vitro and in vivo. Other advantages of GNS/siHSP72/HA included easy synthesis, robust siRNA loading capacity, endosome/lysosome escaping ability, high photothermal conversion efficacy and superior hemo- and biocompatibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Cited by
Zhou, J., Li, M., Hou, Y., Luo, Z., Chen, Q., Cao, H., Huo, R., Xue, C., Sutrisno, L., Hao, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00309 · Cited by 424
Recent advances in nanomaterials for enhanced photothermal therapy of tumors
Hu, J.-J., Cheng, Y.-J., & Zhang, X.-Z. (2018) · Nanoscale · doi:10.1039/c8nr07627h · Cited by 409
Precise nanomedicine for intelligent therapy of cancer
Chen, H., Gu, Z., An, H., Chen, C., Chen, J., Cui, R., Chen, S., Chen, W., Chen, X., Chen, X., et al. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9397-5 · Cited by 409
Self-citationCD44 as a tumor biomarker and therapeutic target
Xu, H., Niu, M., Yuan, X., Wu, K., & Liu, A. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00192-0 · Cited by 389
Chen, W.-H., Luo, G.-F., Lei, Q., Hong, S., Qiu, W.-X., Liu, L.-H., Cheng, S.-X., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.6b06658 · Cited by 367
Metadata
- Authors
- Wang, S., Tian, Y., Tian, W., Sun, J., Zhao, S., Liu, Y., Wang, C., Tang, Y., Ma, X., Teng, Z., & Lu, G.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-09-06
- Volume
- 10
- Issue
- 9
- Pages
- 8578-8590
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2513599763
- Cited by
- 167
- References
- 1
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selectively Sensitizing Malignant Cells to Photothermal Therapy Using a CD44-Targeting Heat Shock Protein 72 Depletion Nanosystem. https://app.cochat.ai/papers/10.1021/acsnano.6b03874
- The paper
- Wang, S., Tian, Y., Tian, W., Sun, J., Zhao, S., Liu, Y., Wang, C., Tang, Y., Ma, X., Teng, Z., & Lu, G. (2016). Selectively Sensitizing Malignant Cells to Photothermal Therapy Using a CD44-Targeting Heat Shock Protein 72 Depletion Nanosystem. ACS Nano. https://doi.org/10.1021/acsnano.6b03874
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.